Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amicus Therapeutics Inc (NASDAQ:FOLD)

10.44
Delayed Data
As of Jun 23
 +0.35 / +3.47%
Today’s Change
4.41
Today|||52-Week Range
10.48
+110.06%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Contact Information

Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury New Jersey 08512
P:(609) 662-2000
Investor Relations:
(609) 662-5000

Employees

Shareholders

Other institutional65.30%
Mutual fund holders53.07%
Individual stakeholders41.95%

Top Executives

John Francis CrowleyChairman & Chief Executive Officer
Bradley L. CampbellPresident & Chief Operating Officer
William D. BairdChief Financial Officer
Ken ValenzanoSenior Vice President-Preclinical Research
Enrique DiloneSenior Vice President-Technical Operations